How can the varied tumour FFPE blocks with HER2 ultra-low influenced on the accurate diagnosis of HER2 in breast cancer

被引：0
|
作者：
Liu, Y. [1 ]
Li, J. [1 ]
Liu, H. [1 ]
Ding, Y. [1 ]
Wu, S. [1 ]
Shang, J. [1 ]
机构：
[1] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China
来源：
VIRCHOWS ARCHIV | 2024年 / 485卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
OFP-01-001
引用
收藏
页码：S1 / S1
页数：1
相关论文
共 50 条
  • [41] Non-genetic HER2 intratumoral heterogeneity with newly discovered HER2 positive tumour cells in gastric cancer: HER2 mRNA expression in amplified HER2 gene tumour cells without HER2 protein over-expression
    Nitta, H.
    Kaito, A.
    Lo, A.
    Murillo, A.
    Munroe, D.
    Ochiai, A.
    Kuwata, T.
    VIRCHOWS ARCHIV, 2020, 477 : S192 - S192
  • [42] Reassessment of HER2 status in breast cancer patients with initially HER2 negative or HER2 unknown primary tumors at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells
    Fehm, T.
    Solomayer, E.
    Uhr, J.
    Wallwiener, D.
    ONKOLOGIE, 2008, 31 : 51 - 51
  • [43] HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer
    Kapil, Ansh
    Spitzmueller, Andreas
    Brieu, Nicolas
    Haneder, Susanne
    Shumilov, Anatoliy
    Meier, Armin
    Cecchi, Fabiola
    Barkell, Alice
    Harder, Nathalie
    Mittermaier, Katrin
    Hidalgo-Sastre, Ana
    Alleze, Regina
    Schick, Markus
    Schmidt, Guenter
    Sade, Hadassah
    Tsuchihashi, Zenta
    Suto, Fumitaka
    Gustavson, Mark
    Barrett, J. Carl
    Carroll, Danielle
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [44] In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer
    Melanie Spears
    Karen J. Taylor
    Alison F. Munro
    Carrie A. Cunningham
    Elizabeth A. Mallon
    Chris J. Twelves
    David A. Cameron
    Jeremy Thomas
    John M. S. Bartlett
    Breast Cancer Research and Treatment, 2012, 132 : 463 - 470
  • [45] The Effect of HER2 Amplification in HER2+Breast Cancer
    Lee, M. K.
    Hurvitz, S. A.
    Tran, B. N.
    Fu, Y.
    Chung, D. U.
    Gornbein, J.
    Apple, S. K.
    Chang, H. R.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S45 - S45
  • [46] Molecular targeting of HER2 for diagnosis and therapy of breast cancer
    Capala, J.
    Kramer-Marek, G.
    Lee, S. B.
    Hassan, M.
    Kiesewetter, D. O.
    Puri, A.
    Chernomordik, V
    Gandjbakhche, A.
    Griffiths, G.
    Blumenthal, R.
    CANCER RESEARCH, 2009, 69 (02) : 349S - 349S
  • [47] Serum HER2 extracellular domain before surgery compared with HER2 in breast cancer
    Zidan, J.
    Mzalbat, R.
    Sharabi, A.
    BREAST, 2015, 24 : S44 - S45
  • [48] HER2 Expression in Breast Cancer With Nonamplified HER2 and Gains of Chromosome 17 Centromere
    Panvichian, Ravat
    Tantiwetrueangdet, Anchalee
    Wongwaisayawan, Sansanee
    Nampoon, Amporn
    Lertsithichai, Panuwat
    Leelaudomlipi, Surasak
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2012, 20 (04) : 367 - 374
  • [49] Her2 FISH amplification in ER/PR/Her2 IHC negative breast cancer
    Sahoo, Sunati
    Hwang, Helena
    CANCER RESEARCH, 2015, 75
  • [50] Impact of the Change of the Criteria for HER2 Immunohistochemistry Interpretation on HER2 Status in Breast Cancer
    Harada, Shuko
    Shen, Dejun
    Wei, Shi
    MODERN PATHOLOGY, 2016, 29 : 44A - 44A
12345